Meeting
2016 Gastrointestinal Cancers Symposium
Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC).
Authors
Michael Teufel
Bayer HealthCare Pharmaceuticals, Whippany, NJ
Michael Teufel , Joachim Kalmus , Mark Daniel Rutstein , Karl Koechert , Henrik Seidel , Joachim Reischl , Adam Skubala , Richardus Vonk , Scott Wilhelm , Svetlana Kobina , Shukui Qin , Rui-hua Xu , Tae Won Kim , Jin Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01584830
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 672)
DOI
10.1200/jco.2016.34.4_suppl.672
Abstract #
672
Poster Bd #
J11
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2019 Gastrointestinal Cancers Symposium
Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.
First Author: Yingmiao Liu
Poster
2018 Gastrointestinal Cancers Symposium
Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts).
First Author: Carlotta Antoniotti
Poster
2014 Gastrointestinal Cancers Symposium
Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer (mCRC).
First Author: Timothy Jay Price